Name: Xilio Therapeutics, Inc. (XLO) Cash Flow Statement
Creator: FinSpry

Xilio Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Xilio Therapeutics, Inc. (XLO) - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Operating Activities
Net Income	-58.24	-76.40	-88.22	-75.80	-55.22
Depreciation & Amortization	1.64	1.90	1.85	1.50	1.07
Stock Based Compensation	6.43	7.38	8.42	4.96	1.30
Change in Working Capital	31.78	-1.66	2.41	-11.80	16.60
Change in Accounts Payable	1.53	-2.06	0.49	-2.82	2.93
Change in Other Working Capital	30.26	0.41	1.52	-8.99	13.68
Other Operating Activities	0.00	0.16	8.24	0.38	0.17
Net Cash from Operating Activities	-18.38	-68.62	-75.72	-80.75	-36.09
Investing Activities
Capital Expenditures	-0.04	-0.49	1.87	-1.10	-2.19
Net Cash from Investing Activities	-0.04	-0.49	-1.87	-1.10	-2.19
Financing Activities
Debt Repayment	-3.38	-6.75	-0.09	-1.09	0.00
Common Stock Issued	6.83	0.20	0.02	116.64	0.16
Other Financing Activities	25.75	0.00	0.00	-0.75	-0.03
Net Cash from Financing Activities	29.20	-6.55	-0.07	260.67	10.03
Summary
Net Change in Cash	10.78	-75.66	-77.66	178.82	-28.25
Cash at Beginning of Period	46.29	121.95	199.61	20.79	0.00
Cash at End of Period	57.07	46.29	121.95	199.61	0.00
Free Cash Flow	-18.41	-69.11	-77.59	-81.85	-38.28
Supplemental Disclosures
Interest Paid	0.06	0.57	0.56	0.49	0.54